These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 26504027

  • 21. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
    Xu D, Fang L, Zhu Q, Hu Y, He Q, Yang B.
    Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Apoptosis and resistance to daunorubicin in human leukemic cells.
    Efferth T, Fabry U, Osieka R.
    Leukemia; 1997 Jul; 11(7):1180-6. PubMed ID: 9205009
    [Abstract] [Full Text] [Related]

  • 30. Effects of inorganic and organic arsenic compounds on growth and apoptosis of human T-lymphoblastoid leukemia cells.
    Hikita E, Arai M, Tanaka S, Onda K, Utsumi H, Yuan B, Toyoda H, Hirano T.
    Anticancer Res; 2011 Dec; 31(12):4169-78. PubMed ID: 22199276
    [Abstract] [Full Text] [Related]

  • 31. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB, Li L, Liu GQ.
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [Abstract] [Full Text] [Related]

  • 32. Targeted and controlled release delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer-modified gold nanoparticles.
    Danesh NM, Lavaee P, Ramezani M, Abnous K, Taghdisi SM.
    Int J Pharm; 2015 Jul 15; 489(1-2):311-7. PubMed ID: 25936625
    [Abstract] [Full Text] [Related]

  • 33. Vitamins C and K3 sensitize human urothelial tumors to gemcitabine.
    Kassouf W, Highshaw R, Nelkin GM, Dinney CP, Kamat AM.
    J Urol; 2006 Oct 15; 176(4 Pt 1):1642-7. PubMed ID: 16952707
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. High-throughput screening for daunorubicin-mediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent.
    Winter SS, Lovato DM, Khawaja HM, Edwards BS, Steele ID, Young SM, Oprea TI, Sklar LA, Larson RS.
    J Biomol Screen; 2008 Mar 15; 13(3):185-93. PubMed ID: 18310528
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib.
    Li YC, Wang HH, Liao AJ, Fu BB, Zhang R, Li J, Yang Y, Liu ZG, Yang W.
    Eur Rev Med Pharmacol Sci; 2014 Mar 15; 18(10):1465-72. PubMed ID: 24899604
    [Abstract] [Full Text] [Related]

  • 38. Relationship between daunorubicin concentration and apoptosis induction in leukemic cells.
    Masquelier M, Zhou QF, Gruber A, Vitols S.
    Biochem Pharmacol; 2004 Mar 15; 67(6):1047-56. PubMed ID: 15006541
    [Abstract] [Full Text] [Related]

  • 39. Decreased expression of nucleophosmin/B23 increases drug sensitivity of adriamycin-resistant Molt-4 leukemia cells through mdr-1 regulation and Akt/mTOR signaling.
    Wang L, Chen B, Lin M, Cao Y, Chen Y, Chen X, Liu T, Hu J.
    Immunobiology; 2015 Mar 15; 220(3):331-40. PubMed ID: 25457413
    [Abstract] [Full Text] [Related]

  • 40. Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer.
    Taghdisi SM, Abnous K, Mosaffa F, Behravan J.
    J Drug Target; 2010 May 15; 18(4):277-81. PubMed ID: 19943768
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.